Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 14, 2012, Pages 1556-1564

  Luthra, Pratibha Mehta ^a   Kumar, J B Senthil ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Apomorphine; Bromocriptine; Dopamine receptor; Dopamine Replacement Therapy; Ergolines; Non ergolines

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; TERGURIDE;

DRUG RECEPTOR BINDING; DRUG TARGETING; DYSKINESIA; HUMAN; MONOAMINERGIC SYSTEM; NONHUMAN; PARKINSON DISEASE; REVIEW;

ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; BROMOCRIPTINE; DOPAMINE AGONISTS; DRUG DELIVERY SYSTEMS; ERGOLINES; HUMANS; PARKINSON DISEASE; RECEPTORS, DOPAMINE;

EID: 84873167479     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712803832645     Document Type: Review

References (62)

1. Chen, Q.; Thorpe, J.; Keller, J.N. Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. J. Biol. Chem., 2005, 34, 30009-17.
2. Selikhova, M.; Williams, D.R.; Kempster, P.A.; Holton, J.L.; Revesz, T.; Lees, A.J. A clinico-pathological study of subtypes in Parkinson's disease. Brain., 2009, 132, 2947-2957.
3. Jankovic, J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry, 2008, 79, 368-376.
4. Skodda, S.; Flasskamp, A.; Schlegel, U. Instability of syllable repetition as a marker of disease progression in Parkinson's disease: A longitudinal study. Mov. Disord., 2010, 26, 59-64.
5. Fabbrini, G.; Brotchie, J.M.; Grandas, F.; Nomoto, M.; Goetz, C.G. Levodopa-induced dyskinesias. Mov. Disord., 2007, 10, 1379-1389.
6. Hinson, V.K. Parkinson's disease and motor fluctuations. Curr. Treat. Options. Neurol., 2010, 12, 186-199.
7. Voon, V.; Fernagut, P.O.; Wickens, J.; Baunez, C.; Rodriguez, M.; Pavon, N. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet. Neurol., 2009, 8, 1140-1149.
8. Heimer, G.; Rivlin-Etzion, M.; Bar-Gad, I.; Goldberg, J.A.; Haber, S.N.; Bergman, H. Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism. J. Neurosci., 2006, 31, 8101-8114.
9. Factor, S.A.; Weiner, W.J. Parkinson's Disease: Diagnosis and Clinical Management, Demos Medical Publishing: New York, 2002.
10. Ponce, F.A.; Lozano, A.M. The most cited works in Parkinson's disease. Mov. Disord., 2011, 26, 380-390.
11. The International Union of Basic and Clinical Pharmacology: Dopamine receptors. http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=20. (Accessed May 23, 2011).
12. Kvernmo, T.; Houben, J.; Sylte, I. Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr. Top. Med. Chem., 2008, 8, 1049-1067.
13. Poewe, W.; Antonini, A.; Zijlmans, J.C.; Burkhard, P.R.; Vingerhoets, F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin. Interv. Aging, 2010, 5, 229-238.
14. Rascol, O.; Brooks, D.J.; Korczyn, A.D.; De Deyn, P.P.; Clarke, C.E.; Lang, A.E.; Abdalla, M. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov. Disord., 2006, 21, 1844-1850.
15. Fici, G.J.; Wu, H.; VonVoigtlander, P.F.; Sethy, V.H. D1 dopamine receptor activity of anti-parkinsonian drugs. Life Sci., 1997, 60, 1597-1603.
16. Mitsutoshi, Y and Tadahisa, U. Dopamine agonists and valvular heart disease in patients with Parkinson's disease: evidence and mystery. J. Neurol., 2007, 254, 74-78.
17. Schild, H.O. Some aspects of receptor pharmacology of ergotamine. Postgrad. Med. J., 1976, 52suppl 1:9-11.
18. Wiggins, J.; Skinner, C. Bromocriptine induced pleuropulmonary fibrosis. Thorax, 1986, 4, 328-330.
19. Müller, T.; Fritze, J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin. Neuropharmacol., 2003, 3,109-111.
20. Waller, E.A.; Kaplan, J. Pergolide-associated valvular heart disease. Compr. Ther., 2006, 32, 94-101.
21. U.S. Food and Drug Administration: Protecting and promoting your health: Drugs: Public Health Advisory-Pergolide (Marketed as Permax). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformati onforPatientsandProviders/DrugSafetyInformationforHeathcareProfessi onals/PublicHealthAdvisories/ucm051285.html (Accessed May 23, 2011).
22. Huang, X.P.; Setola, V.; Yadav, P.N.; Allen, J.A.; Rogan, S.C.; Hanson, B. J; Revankar, C.; Robers, M.; Doucette, C.; Roth, B.L. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol. Pharmacol., 2009, 76, 710-722.
23. Gustafsson, B.I.; Tømmerås, K.; Nordrum, I.; Loennechen, J.P.; Brunsvik, A.; Solligård, E.; Fossmark, R.; Bakke, I.; Syversen, U.; Waldum, H. Long-term serotonin administration induces heart valve disease in rats. Circulation, 2005, 111, 1517-1522.
24. Setola, V.; Hufeisen, S.J.; Grande-Allen, K.J.; Vesely, I.; Glennon, R.A.; Blough, B.; Rothman R.B.; Roth B.L. 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol., 2003, 63, 1223-1229.
25. Hofmann, C.; Penner, U.; Dorow, R.; Pertz, H.H.; Jähnichen, S.; Horowski, R.; Latté, K. P, Palla, D.; Schurad, B. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin. Neuropharmacol., 2006, 29, 80-86.
26. Mehta, P.; Kumar, Y.; Saxena, A.K.; Gulati, A.; Singh, H.K.; Anand, N. Synthesis of cis and trans-1-substituted-1,2,3,4,4a5,6,11a-octahydro-6H-pyrido [3,2-b]carbazoles, 4-substituted-1,2,3,4,4a,5,6,11coctahydro-7Hpyrido [2,3-c]carbazole, cis-methyl-1,2,3,4,4a,5,6,12-octahydro-7Hpyrido[2,3-c]acridine and cis-1-methyl-2,3,4,4a,5,12,12a-octahydro [3,2-b]acridine. A new class of anti-Parkinsonian agents. Ind. J. Chem., 1991, 30, 213-221.
27. Goulet, M.; Madras, B.K. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Ther., 2000, 292, 714-724.
28. Mottola, D.M.; Brewster, W.K.; Cook, L.L.; Nichols, D.E.; Mailman, R.B. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. Clin. Neuropharmacol., 1998, 21, 339-343.
29. Blanchet, P.J.; Fang, J.; Gillespie, M.; Sabounjian, L.; Locke, K.W.; Gammans, R.; Mouradian M.M.; Chase T.N. Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease, Clin. Neuropharmacol., 1998, 21, 339-343.
30. Jing, Z.; Bing, X.; Xuechu, Z.; Ao, Z. Dopamine D1 receptor ligands: Where are we now and where are we going. Med. Res. Rev., 2009, 29, 272-294.
31. Watts, R.L.; Lyons, K.E.; Pahwa, R.; Sethi, K.; Stern, M.; Hauser, R.A. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov. Disord. 2010, 25, 858-866.
32. Voon, V.; Fernagut, P.O.; Wickens, J.; Baunez, C.; Rodriguez, M.; Pavon, N. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet. Neurol., 2009, 8, 1140-1149.
33. Dodd, M.L.; Klos, K.J.; Bower, J.H.; Geda, Y.E.; Josephs, K.A.; Ahlskog, J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch. Neurol., 2005, 62, 1377-1381.
34. Martín, F.F.; Martín, G.T. Pathological gambling and hypersexuality due to dopaminergic treatment in Parkinson' disease. Actas. Esp. Psiquiatr., 2009, 37, 118-122.
35. Kenangil, G.; Ozekmekçi, S.; Sohtaoglu, M.; Erginöz, E.; Compulsive behaviors in patients with Parkinson's disease, Neurologist., 2010, 16, 192-195.
36. Fasano, A.; Elia, A.E.; Soleti, F.; Guidubaldi, A.; Bentivoglio, A.R. Punding and computer addiction in Parkinson's disease. Mov. Disord., 2006, 21, 1217-1218
37. Bienfait, K.L.; Menza, M.; Mark, M.H.; Dobkin, R. D, Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists. J. Clin. Neurosci., 2010, 17, 539-540.
38. O'Sullivan, S.S.; Djamshidian, A.; Evans, A.H.; Loane, C.M.; Lees, A.J.; Lawrence, A.D. Excessive hoarding in Parkinson's disease. Mov. Disord., 2010, 25, 1026-1033.
39. Kataoka, H.; Ueno, S. Compulsive singing associated with a dopamine agonist in Parkinson disease. Cogn. Behav. Neurol., 2010, 23, 140-141.
40. Voon, V.; Potenza, M.N.; Thomsen, T. Medication-related impulse control and repetitive behaviors in Parkinson's disease. Curr. Opin. Neurol, 2007, 20, 484-492.
41. Ceravolo, R.; Frosini, D.; Rossi, C.; Bonuccelli, U.; Impulse control disorders in Parkinson's disease:definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat. Disord., 2009, 15, S111-115.
42. Borek, L.L.; Friedman, J.H.; Levodopa addiction in idiopathic Parkinson disease. Neurology, 2005, 65, 1508.
43. Suzuki, M.; Hirai, T.; Ito, Y.; Sakamoto, T.; Oka, H.; Kurita, A.; Inoue, K. Pramipexole-induced antecollis in Parkinson's disease. J. Neurol. Sci., 2008, 264, 195-197.
44. Uzawa, A.; Mori, M.; Kojima, S.; Mitsuma, S.; Sekiguchi, Y.; Kanesaka, T.; Kuwabara, S. Dopamine agonist induced antecollis in Parkinson's disease. Mov. Disord., 2009, 24, 2408-2411.
45. Kleiner, F.G.; Fisman, D.N.; Risk factors for the development of pedal edema in patients using pramipexole. Arch Neurol., 2007, 64, 820-824.
46. Domperidone as a Treatment for Dopamine Agonist-Induced Peripheral Edema in Patients With Parkinson's Disease. http://clinicaltrials.gov/ct2/show/NCT00305331. (Accessed June 23, 2011).
47. Yue, J.L.; Okamura, H.; Goshima, Y.; Nakamura, S.; Geffard, M.; Misu, Y. Baroreceptor-aortic nerve-mediated release of endogenous L-3,4-dihydroxyphenylalanine and its tonic depressor function in the nucleus tractus solitarii of rats. Neuroscience., 1994, 1, 145-161.
48. Braunwald, E.; Edema. in: Harrisons Principles of Internal Medicine 16th ed.: Kasper, D.L.; Fauci, A.S.; Longo, D.L.; Braunwald, E.; Hauser, S.L.; Jameson, J.L. Ed.; McGraw-Hill, New York, 2005, pp. 212-216.
49. Delfino, M.; Kalisch, R.; Czisch, M.; Larramendy, C.; Ricatti, J.; Taravini, I. R, Trenkwalder, C.; Murer, M.G.; Auer, D.P.; Gershanik, O.S. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology, 2007, 32, 1911-1921.
50. Fici, G.J.; Wu, H.; VonVoigtlander, P.F.; Sethy, V. H, D1 dopamine receptor activity of anti-parkinsonian drugs. Life Sci., 1997, 60, 1597-1603.
51. Peacock, L.; Hansen, F.; Mørkeberg, J.; Gerlach. Chronic Dopamine D1, Dopamine D2 and Combined Dopamine D1 and D2 Antagonist Treatment in Cebus Apella Monkeys: Neuropsychopharmacology, 1999, 1, 35-43.
52. Higley, A.E.; Spiller, K.; Grundt, P.; Newman, A.H.; Kiefer, S.W.; Xi, Z.X.; Gardner, E.L. PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J. Psychopharmacol., 2011, 25, 263-273.
53. Marona, L.D.; Thisted, R.A.; Nichols, D.E. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology, 2005, 180, 427-435.
54. Chen, J.; Rusnak, M.; Luedtke, R.R.; Sidhu, A. D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J. Biol. Chem., 2004, 279, 39317-39330.
55. Lewis, M.M.; Huang, X.; Nichols, D.E.; Mailman, RB. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. CNS. Neurol. Disord. Drug Targets, 2006, 3, 345-353.
56. Le, W.D.; Jankovic. J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging, 2001, 6, 389-396.
57. Snow, B.J.; Macdonald, L.; Mcauley, D.; Wallis, W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin. Neuropharmacol., 2000, 23, 82-85.
58. Hauser, R.A.; Schwarzschild, M.A. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging, 2005, 6, 471-482.
59. Ferguson, M.C.; Nayyar, T.; Deutch, A.Y.; Ansah, T.A. 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Neuropharmacology, 2010, 59, 31-36.
60. Thiriez, C.; Villafane, G.; Grapin, F.; Fenelon, G.; Remy, P.; Cesaro, P. Can nicotine be used medicinally in Parkinson's disease? Expert Rev. Clin. Pharmacol., 2011, 4, 429-436.
61. Chien, E.Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G.W.; Hanson, M.A.; Shi, L.; Newman, A.H.; Javitch, J.A.; Cherezov, V.; Stevens, R.C. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science, 2010, 330, 1091-1095.
62. Prakash, A.; Luthra, P.M. Insilico study of the A(2A)R-D (2)R kinetics and interfacial contact surface for heteromerization, AminoAcids, 2012, Jan 26. DOI 10.1007/s00726-012-1218-x, 2012).